Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
649
ISIN
US05280R1005
Website
AUTL Metrics
BasicAdvanced
$551M
-
-$0.89
1.76
-
Price and volume
Market cap
$551M
Beta
1.76
52-week high
$2.17
52-week low
$1.11
Average daily volume
2.5M
Financial strength
Current ratio
9.244
Quick ratio
8.735
Long term debt to equity
83.041
Total debt to equity
83.842
Interest coverage (TTM)
-1,590.89%
Management effectiveness
Return on assets (TTM)
-20.27%
Return on equity (TTM)
-49.97%
Valuation
Price to revenue (TTM)
61.141
Price to book
1.48
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-1.941
Growth
Revenue change (TTM)
-14.16%
Earnings per share change (TTM)
-24.77%
3-year revenue growth (CAGR)
59.35%
3-year earnings per share growth (CAGR)
-21.39%
AUTL News
AllArticlesVideos
Autolus Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·6 days ago
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewsWire·2 weeks ago
I Missed The Quantum Rally - I Won't Miss The Next One
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $551M as of June 04, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of June 04, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of June 04, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.